SAN JOSE, Calif.--(BUSINESS WIRE)--Micrus Endovascular Corporation (Nasdaq: MEND - News) today announced the initiation of its worldwide launch of Neuropath® guide catheter line. The launch of the Neuropath guide catheter demonstrates Micrus’ continued commitment to a more broadly based product portfolio and the development of novel access product technologies.
The Neuropath guide catheter line is designed with a highly flexible and visible tip that allows for ready vascular access, while maintaining good stability. This design is intended to allow neurointerventionalists with better vessel access and greater vessel selection in treating patients with complex anatomies.
“The Neuropath marks our entry into the guide catheter market and therefore represents a 100% incremental revenue opportunity for us,” said John Kilcoyne, Chairman and CEO of Micrus Endovascular. “The Neuropath is another example of Micrus’ commitment to the development of products that deliver clinical advantages to our physicians while bolstering our non-embolic product portfolio.”
About Micrus Endovascular Corporation
Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke. Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide. The Micrus product line enables physicians to gain access to the brain in a minimally invasive manner through the vessels of the circulatory system. Micrus’ proprietary, three-dimensional microcoils automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells accessory devices and products used in conjunction with its microcoils. For more information, visit www.micruscorp.com.
Forward-Looking Statements
Micrus, from time to time, may discuss forward-looking information, including estimated fiscal 2009 revenues. Except for the historical information contained in this release, all forward-looking statements are predictions by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include the risk of inconclusive or unfavorable clinical trial results, the uncertain market for its products, the Company’s ability to obtain, and the timing of, regulatory approvals and clearances for its products, product enhancements or future products, and other risks affecting the Company, including the Company’s involvement in patent litigation with Boston Scientific Corporation, the Company’s limited operating history and history of significant operating losses, fluctuations in quarterly operating results, which are difficult to predict, the Company’s dependence on developing new products or product enhancements, challenges associated with complying with applicable state, federal and international regulations related to sales of medical devices and governing Micrus’ relationships with physicians and other consultants, the Company’s ability to compete with large, well-established medical device manufacturers with significant resources and other risks as detailed from time to time in risk factors and other disclosures in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2008, and other filings with the Securities and Exchange Commission. All forward-looking statements in this release represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intention or obligation to update forward-looking statements.
Contact:
Micrus Endovascular Corporation Gordon Sangster, Vice President, Chief Financial Officer 408-433-1400 gsangster@micruscorp.com or Lippert/Heilshorn & Associates, Inc. Investor Contact: Jody Cain, 310-691-7100 jcain@lhai.com Bruce Voss, 310-691-7100 bvoss@lhai.com
Source: Micrus Endovascular Corporation
